Asha Yabannavar

Title: Asha Yabannavar: Innovator in Monoclonal Antibody Therapy

Introduction

Asha Yabannavar is a prominent inventor based in Lafayette, CA (US). She has made significant contributions to the field of monoclonal antibody therapy, particularly in the treatment of diseases mediated by CD40 signaling. With a total of 6 patents to her name, her work has the potential to impact therapeutic approaches in immunology.

Latest Patents

Asha's latest patents include innovative compositions and methods for therapy using antagonist anti-CD40 monoclonal antibodies. These methods involve administering a therapeutically effective amount of an antagonist anti-CD40 antibody or its antigen-binding fragment to patients in need. The antibodies are designed to be free of significant agonist activity while exhibiting antagonist activity when binding to CD40 antigens on human CD40-expressing cells. This antagonist activity is crucial as it beneficially inhibits the proliferation and differentiation of human CD40-expressing cells, such as B cells.

Career Highlights

Throughout her career, Asha has worked with notable organizations, including Novartis Vaccines & Diagnostics and the University of Washington. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Asha has collaborated with esteemed colleagues such as Niels H Andersen and Jason Bowman. These partnerships have further enriched her research and development efforts in monoclonal antibody therapies.

Conclusion

Asha Yabannavar's innovative work in the field of monoclonal antibodies showcases her dedication to advancing medical therapies. Her contributions are paving the way for new treatment options for patients with diseases influenced by CD40 signaling.